Bristol-Myers Squibb Co reaches 20-day high amid sector rotation
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 07 Jan 26
Source: SeekingAlpha
Bristol-Myers Squibb Co's stock rose by 3.05%, reaching a 20-day high, reflecting positive momentum in the market.
This increase is attributed to sector rotation, as investors are shifting their focus towards companies with strong dividend yields, such as Bristol-Myers Squibb, which recently raised its dividend by 1.6%. The broader market is showing slight gains, with the Nasdaq-100 up 0.07% and the S&P 500 up 0.04%, indicating a favorable environment for dividend-paying stocks.
The implications of this movement suggest that Bristol-Myers Squibb's strong financial health and commitment to shareholders are attracting investor interest, especially in a market that is increasingly valuing stable dividend growth.
Analyst Views on BMY
Wall Street analysts forecast BMY stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BMY is 55.86 USD with a low forecast of 37.00 USD and a high forecast of 68.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
20 Analyst Rating
8 Buy
11 Hold
1 Sell
Moderate Buy
Current: 55.560
Low
37.00
Averages
55.86
High
68.00
Current: 55.560
Low
37.00
Averages
55.86
High
68.00
About BMY
Bristol-Myers Squibb Company is a global biopharmaceutical company. It is engaged in the discovery, development and delivery of transformational medicines for patients facing serious diseases in areas: oncology, hematology, immunology, cardiovascular, neuroscience and other areas. Its growth portfolio includes Opdivo (nivolumab), Opdivo Qvantig (nivolumab and hyaluronidase-nvhy), Yervoy (ipilimumab), Reblozyl (luspatercept-aamt), Opdualag (nivolumab and relatlimab-rmbw), Breyanzi (lisocabtagene maraleucel), Camzyos (mavacamten), Zeposia (ozanimod), Abecma (idecabtagene vicleucel), and Sotyktu (deucravacitinib). Its other growth products include Onureg, Inrebic, and Empliciti. Its legacy portfolio includes Eliquis (apixaban), Revlimid (lenalidomide), Pomalyst/Imnovid (pomalidomide), Sprycel (dasatinib), and Abraxane (paclitaxel albumin-bound particles for injectable suspension). Opdivo (nivolumab) is a fully human monoclonal antibody that binds to the PD-1 on T and NKT cells.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
